NewAmsterdam Pharma (NASDAQ:NAMS) Major Shareholder Sells $869,722.38 in Stock

NewAmsterdam Pharma (NASDAQ:NAMS) major shareholder Nap B.V. Forgrowth sold 33,438 shares of the firm’s stock in a transaction dated Thursday, December 26th. The shares were sold at an average price of $26.01, for a total value of $869,722.38. Following the completion of the transaction, the insider now directly owns 10,727,490 shares in the company, valued at $279,022,014.90. This trade represents a 0.31 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Large shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Nap B.V. Forgrowth also recently made the following trade(s):

• On Monday, December 23rd, Nap B.V. Forgrowth sold 25,132 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $25.49, for a total value of $640,614.68.
• On Friday, December 20th, Nap B.V. Forgrowth sold 49,772 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $25.60, for a total value of $1,274,163.20.
• On Wednesday, December 18th, Nap B.V. Forgrowth sold 100,728 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $26.10, for a total transaction of $2,629,000.80.
• On Thursday, December 12th, Nap B.V. Forgrowth sold 166,011 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $25.39, for a total transaction of $4,215,019.29.
• On Monday, November 18th, Nap B.V. Forgrowth sold 33,273 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $25.08, for a total transaction of $834,486.84.
• On Friday, November 15th, Nap B.V. Forgrowth sold 8,530 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $25.02, for a total value of $213,420.60.

NewAmsterdam Pharma Trading Up 0.4 %

NAMS stock opened at $25.70 on Thursday. The firm has a fifty day moving average price of $22.26 and a two-hundred day moving average price of $19.26. NewAmsterdam Pharma has a 1-year low of $11.18 and a 1-year high of $27.29.

Institutional Investors Weigh In On NewAmsterdam Pharma

A number of institutional investors have recently modified their holdings of the business. Geode Capital Management LLC lifted its holdings in NewAmsterdam Pharma by 1.6% in the third quarter. Geode Capital Management LLC now owns 86,322 shares of the company’s stock worth $1,433,000 after acquiring an additional 1,399 shares during the last quarter. Banque Cantonale Vaudoise acquired a new stake in shares of NewAmsterdam Pharma during the 2nd quarter worth approximately $38,000. Quarry LP lifted its holdings in shares of NewAmsterdam Pharma by 2,469.2% in the 3rd quarter. Quarry LP now owns 6,500 shares of the company’s stock worth $108,000 after purchasing an additional 6,247 shares during the last quarter. Barclays PLC boosted its position in NewAmsterdam Pharma by 1,813.4% during the 3rd quarter. Barclays PLC now owns 7,596 shares of the company’s stock valued at $126,000 after purchasing an additional 7,199 shares during the period. Finally, Bellevue Group AG bought a new position in NewAmsterdam Pharma during the 3rd quarter worth $128,000. Institutional investors own 89.89% of the company’s stock.

Analysts Set New Price Targets

NAMS has been the subject of a number of analyst reports. HC Wainwright assumed coverage on NewAmsterdam Pharma in a report on Monday. They issued a “buy” rating and a $48.00 price target for the company. Needham & Company LLC reissued a “buy” rating and set a $36.00 price target on shares of NewAmsterdam Pharma in a research report on Thursday, December 5th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $31.00 price target on shares of NewAmsterdam Pharma in a report on Thursday, September 5th. Piper Sandler reissued an “overweight” rating and set a $37.00 price objective on shares of NewAmsterdam Pharma in a report on Monday, September 23rd. Finally, Scotiabank boosted their target price on shares of NewAmsterdam Pharma from $35.00 to $47.00 and gave the stock a “sector outperform” rating in a research report on Wednesday, December 11th. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $38.17.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.